Discover one of our 28 local entrepreneurial communities »
Be the first to know as we launch in new countries and markets around the globe.
Interested in bringing MIT Technology Review to your local market?
Unsupported browser: Your browser does not meet modern web standards. See how it scores »
Several gene therapies are or will soon be in late-stage human trials. One of them could be the first to get FDA approval for sale in the U.S.
Despite promising results in controlling neuronal activity, leaders in brain research still wrestle over turning their work into treatments.
From millions of random mutations, scientists identify a virus that could make gene therapy for inherited retinal diseases safer and more effective.
A light-sensitive polymer could offer a new way to develop artificial retinas.
A device that uses no externally visible gear enables patients to read letters and see faces.
The technique would retrain cells that typically don’t respond to light.
A small biotech firm is the second company to start human tests of embryonic stem-cell therapy.
Delivering light-sensitive proteins to the retinas of blind mice restores some vision.
Embryonic stem cells growing in a dish can spontaneously form complex structures resembling the retina—a discovery that could one day help restore sight to the blind.